Clinical Analysis of Femur Shaft Insufficiency Fractures

다국어 초록 (Multilingual Abstract)

Background: To characterize the recently issued femur shaft insufficiency fracture in terms of a patient’s own epidemiological status.
Methods: Fourteen patients were treated for insufficiency fracture from July 2002 to June 2008, excluding cases including the risk factors of insufficiency fracture. All patients were female, and their mean age was 75.6 years (range, 65 to 89 years). The mean follow-up period was 50.6 months (range, 14 to 86 months).
Results: The mean body weight of the Koreans in the same age group was 58.1 ± 9.7 kg, and the mean height was 155.5 ± 8.8 cm. The mean body weight of our insufficiency fracture patients was 45.7 kg and it was statistically significantly lower than that of the Koreans in the same age group (p < 0.001). The mean height was 147.3 cm and it was significantly shorter than the mean height of the Koreans in the same age group (p = 0.002). In regard to menopausal time, the mean menopausal time of the Koreans was 48.0 ± 4.2 years, it was 44 years in our study, as menopause occurred statistically significantly earlier (p = 0.017). The patients with insufficiency fracture showed statistically lower weight, shorter stature and an earlier menopausal period than that of the general population.
Conclusions: In early menopausal, underweight, and short patients prescribed osteoporosis medication for an extended period of time, if predromal symptom is present, it is necessary to suspect insufficiency fracture of the femur.

참고문헌 (Reference)

1 Bone HG, "Ten years' experience with alendronate for osteoporosis in postmenopausal women" 350 (350): 1189-1199, 2004

2 Mashiba T, "Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib" 15 (15): 613-620, 2000

3 Goh SK, "Subtrochanteric insufficiency fractures in patients on alendronate therapy: a caution" 89 (89): 349-353, 2007

4 Odvina CV, "Severely suppressed bone turnover: a potential complication of alendronate therapy" 90 (90): 1294-1301, 2005

5 Black DM, "Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group" 348 (348): 1535-1541, 1996

6 Fleisch H, "Principles of bone biology" Academic Press 1361-1385, 2002

7 Neviaser AS, "Low-energy femoral shaft fractures associated with alendronate use" 22 (22): 346-350, 2008

8 Black DM, "Fracture risk reduction with alendronate in women with osteoporosis:the Fracture Intervention Trial. FIT Research Group" 85 (85): 4118-4124, 2000

9 Sayed-Noor AS, "Case reports: two femoral insufficiency fractures after long-term alendronate therapy" 467 (467): 1921-1926, 2009

10 Fleisch H, "Bisphosphonates: mechanisms of action" 19 (19): 80-100, 1998

11 Schneider JP, "Bisphosphonates and low-impact femoral fractures: current evidence on alendronate-fracture risk" 64 (64): 18-23, 2009

12 Whyte MP, "Bisphosphonate-induced osteopetrosis" 349 (349): 457-463, 2003

13 Lenart BA, "Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate" 358 (358): 1304-1306, 2008